The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Urimar-T Caps
methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate · METHENAMINE 120 mg/1; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 40.8 mg/1; PHENYL SALICYLATE 36.2 mg/1; METHYLENE BLUE 10.8 mg/1; HYOSCYAMINE SULFATE .12 mg/1 · Capsule · Oral · Allegis Pharmaceuticals, LLC
NDC 28595-0224-60 · 60 CAPSULE in 1 BOTTLE · UNAPPROVED DRUG OTHER · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$649.00
Reported to Texas DSHS · 2025 annual filing · Allegis Pharmaceuticals, LLC
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicaid spend (2024)
$13,786
32 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate (oral solid) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Regulatory
- Application
- —
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- —
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate (Capsule)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Allegis Pharmaceuticals, LLC | METHENAMINE 120 mg/1; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 40.8 mg/1; PHENYL SALICYLATE 36.2 mg/1; METHYLENE BLUE 10.8 mg/1; HYOSCYAMINE SULFATE .12 mg/1 | Aug 26, 2026 | Sep 3, 2026 |
| Allegis Pharmaceuticals, LLC | METHENAMINE .12 mg/1; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 120 mg/1; PHENYL SALICYLATE 10.8 mg/1; METHYLENE BLUE 36.2 mg/1; HYOSCYAMINE SULFATE 40.8 mg/1 | Jul 22, 2026 | Aug 22, 2026 |
| Allegis Pharmaceuticals, LLC | HYOSCYAMINE SULFATE .12 mg/1; METHENAMINE 120 mg/1; METHYLENE BLUE 10.8 mg/1; PHENYL SALICYLATE 36.2 mg/1; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 40.8 mg/1 | Jul 15, 2026 | Jul 19, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Urimar-T Caps — NDC 28595-0224-60," retrieved September 3, 2026, https://drugdashboards.com/drug/28595022460.
Free to cite with attribution — see how the data is put together.